Pillar 1 - FTO (new thread), page-366

Thanks mate. Let me ask slightly differently.

I get your point that the reg approval will depend on Bisantrene being better/ safer than current standard of care as a prerequisite. Just going back to my question then should Bisantrene be priced (or valued) not just as a safer replacement for existing standard of care but should it include the delta for better patient outcomes and no further costs to insurers/ patient (payer)? Whether the standard of care is a branded medicine or generic would the above make sense?

For eg., if I am buying a Sony TV to replace my low priced Chinese (random example) LED TV I would not only pay to have a better looking and better performing TV but also hopefully lower total cost of ownership with less maintenance issues and longer life. So I am not paying a like for like for the TV but way more considering everything.

Not sure if it is a good analogy but I am just putting it out there.